Compare ATYR & AOMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATYR | AOMR |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.2M | 191.5M |
| IPO Year | 2015 | 2019 |
| Metric | ATYR | AOMR |
|---|---|---|
| Price | $0.36 | $8.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | $3.67 | ★ $11.08 |
| AVG Volume (30 Days) | ★ 728.9K | 131.2K |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 14.18% |
| EPS Growth | 6.98 | ★ 53.85 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $190,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.37 | $7.94 |
| 52 Week High | $1.12 | $9.82 |
| Indicator | ATYR | AOMR |
|---|---|---|
| Relative Strength Index (RSI) | 25.94 | 34.41 |
| Support Level | N/A | $8.00 |
| Resistance Level | $0.59 | $9.24 |
| Average True Range (ATR) | 0.03 | 0.15 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 2.51 | 26.67 |
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in first and second lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation, across interest rate and credit cycles. The company operates in a single operating segment, which is to acquire, invest in, and finance mortgage-related assets.